I love Tedolizid for gram positive infections and believe it will bear much fruit over the next 12-18 months. To me the next step with TSRX gram negative product could be a real game changer as drug resistance to the 'penems could be even more clinically important. Does anyone have any insight as to when Trius will be able to enter Phase I trials for the gyrase inhibitors? Would appreciate any constructive input
Good question. Though I can't answer your question, my understanding is that the gram negative bacteria is a real challenge and very difficult to treat. That would be a huge development if it were to come about.